A metaresearch group at Tilburg University in the Netherlands investigates scientists’ research methods and operations, scrutinizing questionable practices such as selective reporting of statistical tests and data massaging. The group instead advocates for practices such as preregistering studies and making experimental data immediately available for open external review and verification. Its members are optimistic that “the perverse incentives of careerist academia, to hoard data and sacrifice rigor for headline-generating findings, will ultimately be fixed.”
Breakfast: My favorite breakfast during this program was leftovers from the night before — it was easy and usually had all the elements I needed to feel full and jumpstart my day. If there was leftover protein, I might throw it over some greens and make a salad. If there was soup, that was always perfect too. When I was feeling breakfast-y, eggs did the trick with some roasted veggies.
Now, The Whole30 offers a stand-alone, step-by-step plan to break unhealthy habits, reduce cravings, improve digestion, and strengthen your immune system. The Whole30 prepares participants for the program in five easy steps, previews a typical thirty days, teaches the basic meal preparation and cooking skills needed to succeed, and provides a month’s worth of recipes designed to build confidence in the kitchen and inspire the taste buds. Motivating and inspiring with just the right amount of signature tough love, The Whole30 features real-life success stories, an extensive quick-reference FAQ, detailed elimination and reintroduction guidelines, and more than 100 recipes using familiar ingredients, from simple one-pot meals to complete dinner party menus.
The WHO trial (so named because the international team of principal investigators contained World Health Organization members) tested the potential of clofibrate, a “pre-statin” cholesterol-lowering agent, to reduce heart attack morbidity and mortality. The investigators ultimately concluded that clofibrate "cannot be recommended as a lipid-lowering drug for community-wide primary prevention of ischaemic heart disease.” Nevertheless, clofibrate remained in use until 2002, when it was pulled for increasing cancer rates. In their review of studies such as the WHO trial, Uffe Ravnskov and David Diamond observe, “Despite the largely disappointing findings from 50 years of cholesterol lower[ing] trials, the indictment and conviction of cholesterol as the causal agent in CVD [cardiovascular disease] has stood the test of time. … [Yet] the grand effort to reduce cholesterol as a strategy to improve health has failed.”